Programs Opioids Clinical Primer Resources BC’s Guideline for the Clinical Management of Opioid Addiction (2017)

BC’s Guideline for the Clinical Management of Opioid Addiction (2017)

Evidence, Guidelines and Recommendations

In June of 2017, the British Columbia Centre on Substance Use (BCCSU) became responsible for the education and training pathways and clinical care guidance for prescribers of opioid use disorder treatment in BC. Amidst a provincial overdose crisis, British Columbia made concerted efforts to address gaps in the provision of evidence-based treatment options and care for individuals with opioid use disorder, including the development of provincial guidelines as well as the creation of its aligned training program, the Provincial Opioid Addiction Treatment Support Program.

Details

Category

Evidence, Guidelines and Recommendations

Format

PDF Document

Downloads

22

Added

Aug 25, 2025

Tags

Psychiatry

Pain

Mental Health

Substance Use Disorders

Primary Care

Internal Medicine

Emergency Medicine

Related Resources

Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline

The objective of this guideline is to provide clinical recommendations for the initiation, maintenance and discontinuation of buprenorphine/naloxone maintenance treatment in the ambulatory treatment of adults and adolescents with opioid dependence in Ontario.

The objective of this guideline is to provide clinical recommendations for the initiation, maintenance and discontinuation of buprenorphine/naloxone maintenance treatment in the ambulatory treatment of adults and adolescents with opioid dependence in Ontario.

Health Quality Ontario Standards: Opioid Prescribing for Chronic Pain

This quality standard includes: quality statements, patient reference guide, recommendations for adoption and a getting started guide.

This quality standard includes: quality statements, patient reference guide, recommendations for adoption and a getting started guide.

Recommendations for the use of slow-release oral morphine as opioid agonist therapy

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

McMaster University

Learn more

Info

Stay up to date

© 2026 McMaster University & Others | 1280 Main St. W. | Hamilton, Ontario L8S 4L8 | Terms of Use

We use cookies

This website uses cookies in order to enhance the overall user experience.

Essential cookies

There are some cookies that we have to include in order for certain web pages to function. For this reason, they do not require your consent.

machealth_cookie_consent

1 year 1 month 1 day

Used to store the user's cookie consent preferences.
machealth_session

4 hours

Used to identify the user's browsing session.
XSRF-TOKEN

4 hours

Used to secure both the user and our website against cross-site request forgery attacks.

More details

Analytics cookies

We use these for internal research on how we can improve the service we provide for all our users. These cookies assess how you interact with our website.

_ga

2 years 2 months 2 days

Main cookie used by Google Analytics, enables a service to distinguish one visitor from another.
_ga_B6GJX7RG8N

2 years 2 months 2 days

Used by Google Analytics to persist session state.
_gid

1 day

Used by Google Analytics to identify the user.
_gat

1 minute

Used by Google Analytics to throttle the request rate.

More details